$ASTH
Astrana Health, Inc. Stock $asth

$asth Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000162828023038192 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$353.0M	$348.2M
YoY Change	20.0%	9.83%
Cost Of Revenue	$314.1M	$275.4M
YoY Change	24.07%	14.38%
Gross Profit	$38.98M	$72.80M
YoY Change	-5.13%	-4.5%
Gross Profit Margin	11.04%	20.91%
Selling, General & Admin	$37.95M	$29.40M
YoY Change	55.24%	37.46%
% of Gross Profit	97.35%	40.38%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$4.902M	$4.310M
YoY Change	20.65%	-9.36%
% of Gross Profit	12.58%	5.92%
Operating Expenses	$42.85M	$33.70M
YoY Change	50.31%	28.91%
Operating Profit	-$3.870M	$39.08M
YoY Change	-130.76%	-21.98%
Interest Expense	$1.644M	$3.779M
YoY Change	-2795.08%	56.03%
% of Operating Profit		9.67%
Other Income/Expense, Net	$1.856M	-$1.068M
YoY Change	14.85%	-87.9%
Pretax Income	$924.0K	$38.02M
YoY Change	-91.16%	-7.87%
Income Tax	$1.018M	$10.04M
% Of Pretax Income	110.17%	26.42%
Net Earnings	$12.36M	$22.06M
YoY Change	-575.23%	-15.11%
Net Earnings / Revenue	3.5%	6.34%
Basic Earnings Per Share		$0.47
Diluted Earnings Per Share	$0.26	$0.47
COMMON SHARES
Basic Shares Outstanding	58.28M shares	57.56M shares
Diluted Shares Outstanding		46.92M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$296.3M	$277.0M
YoY Change	0.92%	27.48%
Cash & Equivalents	$293.8M	$273.9M
Short-Term Investments	$2.498M	$3.000M
Other Short-Term Assets	$17.45M	$14.00M
YoY Change	17.92%	19.64%
Inventory
Prepaid Expenses
Receivables	$135.8M	$182.8M
Other Receivables	$1.335M	$1.501M
Total Short-Term Assets	$461.5M	$476.2M
YoY Change	6.06%	7.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$44.57M	$150.1M
YoY Change	-65.45%	24.58%
Goodwill	$278.8M	$275.5M
YoY Change	1.14%	7.01%
Intangibles	$71.65M	$74.21M
YoY Change	-6.78%	1.34%
Long-Term Investments	$25.77M	$44.43M
YoY Change	-36.04%	14.05%
Other Assets	$1.877M	$8.586M
YoY Change	-69.01%	40.82%
Total Long-Term Assets	$471.9M	$597.0M
YoY Change	-10.76%	19.46%
TOTAL ASSETS
Total Short-Term Assets	$461.5M	$476.2M
Total Long-Term Assets	$471.9M	$597.0M
Total Assets	$933.4M	$1.073B
YoY Change	-3.17%	13.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.72M	$24.60M
YoY Change	0.97%	-3.29%
Accrued Expenses	$24.71M	$18.90M
YoY Change	30.9%	50.78%
Deferred Revenue	$744.0K	$822.0K
YoY Change	40.11%	51.1%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.50M	$2.991M
YoY Change	3050.24%	-5.41%
Total Short-Term Liabilities	$218.7M	$203.0M
YoY Change	48.43%	29.94%
LONG-TERM LIABILITIES
Long-Term Debt	$258.9M	$206.2M
YoY Change	27.31%	3.55%
Other Long-Term Liabilities	$3.586M	$14.11M
YoY Change	-82.3%	8.8%
Total Long-Term Liabilities	$303.9M	$254.7M
YoY Change	22.61%	8.88%
TOTAL LIABILITIES
Total Short-Term Liabilities	$218.7M	$203.0M
Total Long-Term Liabilities	$303.9M	$254.7M
Total Liabilities	$522.6M	$457.6M
YoY Change	32.23%	17.31%
SHAREHOLDERS EQUITY
Retained Earnings	$243.1M	$230.8M
YoY Change	26.19%	18.18%
Common Stock	$47.00K	$47.00K
YoY Change	0.0%	4.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$614.2M	$593.7M
YoY Change
Total Liabilities & Shareholders Equity	$933.4M	$1.073B
YoY Change	-3.17%	13.76%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$12.36M	$22.06M
YoY Change	-575.23%	-15.11%
Depreciation, Depletion And Amortization	$4.902M	$4.310M
YoY Change	20.65%	-9.36%
Cash From Operating Activities	$19.30M	$15.41M
YoY Change	-77.28%	-142.96%
INVESTING ACTIVITIES
Capital Expenditures	$7.057M	$4.100M
YoY Change	696.5%	-227.77%
Acquisitions
YoY Change
Other Investing Activities	-$4.370M	-$30.77M
YoY Change	-131.02%	530.92%
Cash From Investing Activities	-$11.43M	-$34.88M
YoY Change	-186.56%	331.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.99M	-510.0K
YoY Change	104.28%	-91.84%
NET CHANGE
Cash From Operating Activities	19.30M	15.41M
Cash From Investing Activities	-11.43M	-34.88M
Cash From Financing Activities	11.99M	-510.0K
Net Change In Cash	19.87M	-19.98M
YoY Change	-80.9%	-60.2%
FREE CASH FLOW
Cash From Operating Activities	$19.30M	$15.41M
Capital Expenditures	$7.057M	$4.100M
Free Cash Flow	$12.24M	$11.31M
YoY Change	-85.43%	-134.63%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Entity Central Index Key EntityCentralIndexKey	0001083446
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58283589	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273941000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	288027000	usd
CY2023Q3	ameh	Investment In Privately Held Entity That Does Not Report Net Asset Value InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue	2896000	usd
CY2022Q1	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	14702000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3055000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3021000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	5567000	usd
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1501000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1834000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13953000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14798000	usd
CY2023Q3	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	25040000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	0	usd
CY2022Q4	ameh	Investment In Privately Held Entity That Does Not Report Net Asset Value InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue	896000	usd
CY2023Q3	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	6257000	usd
CY2022Q4	ameh	Fiduciary Accounts Payable Current FiduciaryAccountsPayableCurrent	8065000	usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	17931000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	14237000	usd
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46607356	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46607356	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46575699	shares
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	348173000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	317001000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1033625000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	849955000	usd
CY2023Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	275375000	usd
CY2022Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	240768000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	857648000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29410000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21388000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	4305000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	758270000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	88483000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	91685000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1452000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3104000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4397000	usd
	us-gaap	Interest Expense InterestExpense	5348000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	9617000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	690000	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6763000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-5875000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-17591000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1876000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1318000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4265000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2328000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1068000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8828000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	431000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15524000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	38015000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	41263000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	88914000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	76161000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10042000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17366000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30971000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29537000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	27973000	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	23897000	usd
	us-gaap	Profit Loss ProfitLoss	57943000	usd
	us-gaap	Profit Loss ProfitLoss	46624000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5914000	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	712000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	9582000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2275000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	22059000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	23185000	usd
	us-gaap	Net Income Loss NetIncomeLoss	48361000	usd
	us-gaap	Net Income Loss NetIncomeLoss	48899000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.52
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.47
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.06
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46547502	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44946725	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46527350	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44795295	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46920607	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46152536	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46881567	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45993001	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	544310000	usd
CY2023Q1	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	14217000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-109000	usd
CY2023Q1	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	1250000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	9539000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3445000	usd
CY2023Q1	ameh	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	-120000	usd
CY2023Q1	ameh	Transfer Of Common Control Entities TransferOfCommonControlEntities	-2447000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	551007000	usd
CY2023Q2	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	14237000	usd
CY2023Q2	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	50000	usd
CY2023Q2	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	106000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-464000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4213000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	800000	usd
CY2023Q2	ameh	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	-96000	usd
CY2023Q2	ameh	Temporary Equity Dividends Impact TemporaryEquityDividendsImpact	-3076000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	569753000	usd
CY2023Q3	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	23737000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-63000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5706000	usd
CY2023Q3	ameh	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	-1424000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	597709000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	454107000	usd
CY2022Q1	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	200000	usd
CY2022Q1	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	36000	usd
CY2022Q1	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	1573000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1000000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	457000	usd
CY2022Q1	ameh	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	-1178000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	472638000	usd
CY2022Q2	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	13296000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-253000	usd
CY2022Q2	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	165000	usd
CY2022Q2	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	9250000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3920000	usd
CY2022Q2	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	371000	usd
CY2022Q2	ameh	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	-1374000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	479513000	usd
CY2022Q3	ameh	Net Income Loss Including Portion Attributable To Noncontrolling Interest And Temporary Equity NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity	24604000	usd
CY2022Q3	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	4138000	usd
CY2022Q3	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	28000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-62000	usd
CY2022Q3	ameh	Stock Issued During The Period Value Of Exercise Of Option And Warrants StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants	1046000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3502000	usd
CY2022Q3	ameh	Noncontrolling Interest Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period Value Release Of Hold Back Shares NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares	-120000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	504373000	usd
	us-gaap	Profit Loss ProfitLoss	57943000	usd
	us-gaap	Profit Loss ProfitLoss	46624000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	12846000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13480000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	711000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	703000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	13364000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10477000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2272000	usd
	ameh	Unrealized Gain Loss From Investment In Equity Securities UnrealizedGainLossFromInvestmentInEquitySecurities	-6898000	usd
	ameh	Unrealized Gain Loss From Investment In Equity Securities UnrealizedGainLossFromInvestmentInEquitySecurities	-21894000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3104000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4397000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1022000	usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	4302000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3936000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3054000	usd
	us-gaap	Proceeds From Other Operating Activities ProceedsFromOtherOperatingActivities	0	usd
	us-gaap	Proceeds From Other Operating Activities ProceedsFromOtherOperatingActivities	901000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	46261000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	58325000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	21801000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	21832000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2303000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	31988000	usd
	ameh	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	1246000	usd
	ameh	Increase Decrease In Prepaid Expenses And Other Current Assets IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets	-3228000	usd
	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	40000	usd
	us-gaap	Increase Decrease In Finance Receivables IncreaseDecreaseInFinanceReceivables	0	usd
	ameh	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	5223000	usd
	ameh	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	2843000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	180000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	682000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1119000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	765000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-1808000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-4029000	usd
	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	10108000	usd
	ameh	Increase Decrease In Medical Liabilities IncreaseDecreaseInMedicalLiabilities	37491000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	25154000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-10395000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5215000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3059000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	109000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3118000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	48927000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2811000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4674000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	5614000	usd
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	2200000	usd
	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	4051000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2125000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1750000	usd
	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	25000000	usd
	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	0	usd
	us-gaap	Payments To Acquire Trading Securities Heldforinvestment PaymentsToAcquireTradingSecuritiesHeldforinvestment	2000000	usd
	us-gaap	Payments To Acquire Trading Securities Heldforinvestment PaymentsToAcquireTradingSecuritiesHeldforinvestment	0	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	325000	usd
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21472000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22054000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6438000	usd
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	400000	usd
	ameh	Payments To Equity Method Investments PaymentsToEquityMethodInvestments	700000	usd
	ameh	Payments To Equity Method Investments PaymentsToEquityMethodInvestments	1785000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-54096000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20314000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	2266000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	12676000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	461000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3714000	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	505000	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	417000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1250000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2784000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	9689000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	9648000	usd
	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	0	usd
	us-gaap	Proceeds From Payments To Minority Shareholders ProceedsFromPaymentsToMinorityShareholders	67000	usd
	ameh	Purchase Of Non Controlling Interest PurchaseOfNonControllingInterest	50000	usd
	ameh	Purchase Of Non Controlling Interest PurchaseOfNonControllingInterest	4338000	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	3149000	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1986000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8572000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-25956000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13741000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-49081000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	288027000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	233097000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	274286000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184016000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	7881000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	41811000	usd
	us-gaap	Interest Paid Net InterestPaidNet	9670000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4386000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6626000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	ameh	Temporary Equity Dividends Impact TemporaryEquityDividendsImpact	3076000	usd
	ameh	Temporary Equity Dividends Impact TemporaryEquityDividendsImpact	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	398000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	1000000	usd
	us-gaap	Mortgage Loan Related To Property Sales1 MortgageLoanRelatedToPropertySales1	0	usd
	us-gaap	Mortgage Loan Related To Property Sales1 MortgageLoanRelatedToPropertySales1	16275000	usd
	ameh	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	0	usd
	ameh	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	694000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273941000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	184016000	usd
CY2023Q3	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	345000	usd
CY2023Q3	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	345000	usd
CY2022Q3	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	0	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	274286000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184016000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. (“ApolloMed”) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to participate successfully in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (“NMM”) in December 2017 (the “2017 Merger”). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors. Unless the context dictates otherwise, references in these notes to the financial statements, the “Company,” “we,” “us,” “our,” and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (“VIEs”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed’s subsidiaries and VIEs include management services organizations (“MSOs”), affiliated independent practice associations (“IPAs”), an accountable care organization (“ACO”) participating in the ACO REACH model, and clinical operations. Together, ApolloMed provides value-based care enablement services and care delivery with our consolidated care partners. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company’s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reportable segments changed from one to three in the first quarter of 2023 as a result of certain changes to the information regularly provided to the Company’s chief operating decision makers (“CODMs”) when reviewing the Company’s performance as well as an effort to provide additional transparency to investors and other financial statement users. The three segments identified by the Company are Care Partners, Care Delivery and Care Enablement, which are described as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Partners</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Care Partners segment is focused on building and managing high-quality and high-performance provider networks by partnering with, empowering, and investing in strong provider partners with a shared vision for coordinated care delivery. By leveraging the Company’s unique care enablement platform and ability to recruit, empower, and incentivize physicians to effectively manage total cost of care, the Company is able to organize partnered providers into successful multi-payer risk-bearing organizations which take on varying levels of risk based on total cost of care across membership in all lines of business, including Medicare, Medicaid, commercial, and exchange. Through the Company’s network of IPAs, ACOs, and Restricted Knox-Keene licensed health plan, the Company’s healthcare delivery entities are responsible for coordinating and delivering high-quality care to their patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated IPAs consist of the following: </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Alpha Care Medical Group, Inc. (“Alpha Care”);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Accountable Health Care IPA, a Professional Medical Corporation (“Accountable Health Care”);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jade Health Care Medical Group, Inc. (“Jade”), (v) Access Primary Care Medical Group (“APCMG”); and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All American Medical Group (“AAMG”);</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ACO operates under the APA ACO, Inc. (“APAACO”) brand and participates in the Centers for Medicare & Medicaid Services (“CMS”) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program’s attribution-based risk-sharing model. The Company’s Restricted Knox-Keene licensed health plan is held by For Your Benefit Inc. (“FYB”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Delivery</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Care Delivery segment is a patient-centric, data-driven care delivery organization focused on delivering high-quality and accessible care to all patients. The Company’ care delivery organization includes primary care, multi-specialty care, and ancillary care services. This segment includes the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Primary care clinics, operating under the AMG, a Professional Medical Corporation (“AMG”) and Valley Oaks Medical Group (“VOMG”) brands;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multi-specialty care clinics and medical groups, operating under the ApolloMed Hospitalists, a Medical Corporation (“AMH”), Southern California Heart Centers, a Medical Corporation (“SCHC”), and AllCare Women’s Health brands; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ancillary service providers, operating under the 1 World Medicine Urgent Care Corporation (“1 World”), DMG, Concourse Diagnostic Surgery Center, LLC (“CDSC”), and Sun Clinical Laboratories (“Sun Labs”) brands.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, AP-AMH 2 purchased 100% of the shares of capital stock of AMG, 1 World, and Eleanor Leung M.D., a Professional Medical Corporation from APC-LSMA. As a result of these purchases, these entities are consolidated entities of AP-AMH 2. On May 1, 2023 the Company sold 25% of Eleanor Leung M.D. to two of its physicians. As a result, AP-AMH 2 owns 75% of Eleanor Leung M.D. AMG provides professional and post-acute care services to patients through its network of doctors and nurse practitioners, 1 World is an urgent care center, and Eleanor Leung M.D. provides specialized care for women’s health operating as AllCare Women’s Health. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Care Enablement</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Care Enablement segment is an integrated, end-to-end clinical and administrative platform, powered by the Company’s proprietary technology suite, which provides operational, clinical, financial, technology, management, and strategic services in order to enable success in the delivery of high-quality, value-based care for providers and payers. The Company provides solutions to providers, including independent physicians, provider and medical groups, and accountable care organizations, and payers, including health plans and other risk-bearing organizations. The Company’s platform meets providers and payers where they are, with a wide spectrum of solutions across the total cost of care risk spectrum, ranging from solutions for fee-for-service entities to global risk-bearing entities, and across patient types, including Medicare, Medicaid, commercial, and exchange-insured patients. This segment includes the Company’s wholly owned subsidiaries which operate as management services organizations, NMM and Apollo Medical Management (“AMM”), which enter into long-term management and/or administrative services agreements with providers and payers. By leveraging the Company’s care enablement platform, providers and payers can improve their ability to deliver high-quality care to their patients and achieve better patient outcomes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Affiliates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s other affiliates are not included as a reportable segment and primarily consist of the following real estate operations:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical Property Partners, LLC (“MPP”);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AMG Properties, LLC (“AMG Properties”);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ZLL Partners, LLC (“ZLL”);</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tag-8 Medical Investment Group, LLC (“Tag 8”); and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tag-6 Medical Investment Group, LLC (“Tag 6”).</span></div>These entities are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC’s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2023Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	301800000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	324700000	usd
	ameh	Risk Pool Surplus Or Deficits Settlement Period After Performance Year RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear	P18M
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentrations of Credit RisksThe Company disaggregates revenue from contracts by service type and payer type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	348173000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	317001000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1033625000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	849955000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q4	us-gaap	Goodwill Goodwill	269053000	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	5423000	usd
	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1052000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	275528000	usd
CY2023Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	202283000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	128074000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74209000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	195472000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	118611000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	76861000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3200000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3400000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9500000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10600000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3173000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	12715000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	11573000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10156000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8729000	usd
CY2023Q3	ameh	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	25713000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	72059000	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	40299000	usd
	ameh	Equity Method Investment Additional Investment EquityMethodInvestmentAdditionalInvestment	325000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3104000	usd
	ameh	Equity Method Investments Contribution EquityMethodInvestmentsContribution	700000	usd
	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	0	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	44428000	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	41715000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	4397000	usd
	ameh	Equity Method Investment Funding Reclassified To Loan Receivable EquityMethodInvestmentFundingReclassifiedToLoanReceivable	2125000	usd
	ameh	Equity Method Investments Contribution EquityMethodInvestmentsContribution	1785000	usd
	ameh	Equity Method Investments Consolidated EquityMethodInvestmentsConsolidated	6418000	usd
	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	400000	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	38954000	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	45832000	usd
CY2023Q3	ameh	Equity Method Investment Additional Investment EquityMethodInvestmentAdditionalInvestment	0	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2104000	usd
CY2023Q3	ameh	Equity Method Investments Contribution EquityMethodInvestmentsContribution	700000	usd
CY2023Q3	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	0	usd
CY2023Q3	us-gaap	Equity Method Investments EquityMethodInvestments	44428000	usd
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	43820000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1452000	usd
CY2022Q3	ameh	Equity Method Investment Funding Reclassified To Loan Receivable EquityMethodInvestmentFundingReclassifiedToLoanReceivable	0	usd
CY2022Q3	ameh	Equity Method Investments Contribution EquityMethodInvestmentsContribution	100000	usd
CY2022Q3	ameh	Equity Method Investments Consolidated EquityMethodInvestmentsConsolidated	6418000	usd
CY2022Q3	us-gaap	Equity Method Investment Sold Carrying Amount EquityMethodInvestmentSoldCarryingAmount	0	usd
CY2022Q3	us-gaap	Equity Method Investments EquityMethodInvestments	38954000	usd
CY2023Q3	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2022Q3	us-gaap	Equity Method Investment Other Than Temporary Impairment EquityMethodInvestmentOtherThanTemporaryImpairment	0	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9209000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10473000	usd
CY2023Q3	ameh	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	4947000	usd
CY2022Q4	ameh	Specialty Capitation Payable Current SpecialtyCapitationPayableCurrent	4229000	usd
CY2023Q3	ameh	Subcontractor Ipa Payable SubcontractorIPAPayable	3781000	usd
CY2022Q4	ameh	Subcontractor Ipa Payable SubcontractorIPAPayable	2415000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4155000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2709000	usd
CY2023Q3	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	1840000	usd
CY2022Q4	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	3304000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	822000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	531000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15421000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15301000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12961000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10600000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	53136000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	49562000	usd
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	The Company’s medical liabilities consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period (restated)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,783 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473,167 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(547,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(622,178)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435,028)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,884 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	81255000	usd
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	55783000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	6157000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	1609000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	642880000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	469518000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-13251000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	3649000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	629629000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	473167000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	547212000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	368851000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	74966000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	66177000	usd
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	622178000	usd
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	435028000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	2656000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Period Increase Decrease LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease	-647000	usd
CY2023Q3	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	97519000	usd
CY2022Q3	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	94884000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	211813000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	207327000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	2991000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	619000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2609000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3319000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	206213000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	203389000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	158000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3234000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7895000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	181164000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1182000	usd
CY2023Q3	ameh	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	18180000	usd
CY2023Q3	us-gaap	Line Of Credit LineOfCredit	211813000	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2600000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3300000	usd
	ameh	Stock Issued During Period Shares Merger StockIssuedDuringPeriodSharesMerger	41048	shares
	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	270081	shares
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10569340	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10299259	shares
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5706000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3502000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13364000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10477000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	33700000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	859850	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.88
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y2M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10300000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	125000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.00
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3300000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	50000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.10
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	684850	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.66
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y11M1D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7000000.0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	589522	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	21.80
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y6M3D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6700000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	125000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1300000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	41603	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
	ameh	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod	281742	shares
	ameh	Warrant Issued During Period Value Stock Options Exercised WarrantIssuedDuringPeriodValueStockOptionsExercised	2000000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.348
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.388
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.47
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.52
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.47
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.50
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46547502	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44946725	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46920607	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46152536	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.06
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46527350	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44795295	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46881567	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45993001	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46547502	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44946725	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	30888	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46920607	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46152536	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46527350	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44795295	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	10409	shares
	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46881567	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45993001	shares
CY2023Q3	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P10Y
CY2023Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
	ameh	Lessee Operating Lease Termination Period If Applicable LesseeOperatingLeaseTerminationPeriodIfApplicable	P1Y
	ameh	Lessee Finance Lease Termination Period If Applicable LesseeFinanceLeaseTerminationPeriodIfApplicable	P1Y
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1800000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1800000	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1500000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	1000000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2187000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1655000	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	202000	usd
CY2022Q3	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	138000	usd
CY2023Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	35000	usd
CY2022Q3	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	17000	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	307000	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	132000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	2117000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	1678000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	5570000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	4780000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	505000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	422000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	80000	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	54000	usd
	us-gaap	Sublease Income SubleaseIncome	806000	usd
	us-gaap	Sublease Income SubleaseIncome	464000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2021000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5925000	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	171000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	24534000	usd
	us-gaap	Lease Cost LeaseCost	5349000	usd
	us-gaap	Lease Cost LeaseCost	4792000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	2016000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	1712000	usd
CY2023Q3	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	202000	usd
CY2022Q3	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	17000	usd
CY2023Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	35000	usd
CY2022Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	138000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	5636000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	4758000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	505000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	54000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	80000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	422000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10M2D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M13D
CY2023Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M4D
CY2022Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M28D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0575
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0492
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0519
CY2022Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0433
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1237000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	194000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4734000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	719000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4503000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	556000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4255000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	302000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3890000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	243000	usd
CY2023Q3	ameh	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	11840000	usd
CY2023Q3	ameh	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	7000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	30459000	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	1850000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3528000	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	655000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21006000	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1195000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	348173000	usd
CY2023Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	275375000	usd
CY2023Q3	ameh	General And Administrative Expenses And Depreciation And Amortization GeneralAndAdministrativeExpensesAndDepreciationAndAmortization	33715000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	309090000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	39083000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	317001000	usd
CY2022Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	240768000	usd
CY2022Q3	ameh	General And Administrative Expenses And Depreciation And Amortization GeneralAndAdministrativeExpensesAndDepreciationAndAmortization	26142000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	266910000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	50091000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1033625000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	857648000	usd
	ameh	General And Administrative Expenses And Depreciation And Amortization GeneralAndAdministrativeExpensesAndDepreciationAndAmortization	87494000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	945142000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	88483000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	849955000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	691566000	usd
	ameh	General And Administrative Expenses And Depreciation And Amortization GeneralAndAdministrativeExpensesAndDepreciationAndAmortization	66704000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	758270000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	91685000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	30313000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	2125000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	896000	usd
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	38849000	usd
CY2023Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	21915000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	135235000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5567000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	145866000	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	21259000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21259000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1656000	usd
	ameh	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Paid FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationPaid	1000000	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21915000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	900000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5600000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	870000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	6251000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	6571000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	21138000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	usd
	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2272000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	870000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	6251000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	6571000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	18866000	usd
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-23-038192-index-headers.html	Edgar Link	pending
0001628280-23-038192-index.html	Edgar Link	pending
0001628280-23-038192.txt	Edgar Link	pending
0001628280-23-038192-xbrl.zip	Edgar Link	pending
ameh-20230930.htm	Edgar Link	pending
ameh-20230930.xsd	Edgar Link	pending
ameh-20230930_g1.jpg	Edgar Link	pending
ex3112023093010-q.htm	Edgar Link	pending
ex3122023093010-q.htm	Edgar Link	pending
ex3132023093010-q.htm	Edgar Link	pending
ex322023093010-q.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
ameh-20230930_cal.xml	Edgar Link	unprocessable
ameh-20230930_def.xml	Edgar Link	unprocessable
ameh-20230930_lab.xml	Edgar Link	unprocessable
ameh-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ameh-20230930_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASTH
Astrana Health, Inc. Stock $asth

2023 Q4 Form 10-Q Financial Statement

#000162828023038192 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH Astrana Health, Inc. Stock $asth

2023 Q4 Form 10-Q Financial Statement

#000162828023038192 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASTH
Astrana Health, Inc. Stock $asth